|
For any enquiries or feedback, kindly send an email to:
New BioMedicine LLC
220 Bush Street, Suite 660
San Francisco, CA 94104
Tel: (415) 367-3525
email: kpaul@newbiomedicine.com |
|
|
Sample Report:
VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
|
| |
Basket Reports: |
 |
Specific theme-based reports at a value price
|
View Package |
|
|
